DUBLIN – Actelion Pharmaceuticals Ltd. reported Tuesday on its ongoing delicate balancing act of ramping up sales of its next-generation endothelin receptor antagonist (ERA), Opsumit (macitentan), while managing the decline of its venerable blockbuster, Tracleer (bosentan), the first product of that class to gain approval for treating pulmonary arterial hypertension (PAH).